O3–06–05: Sustained cognitive benefit in patients with mild cognitive impairment (MCI) upon prolonged treatment with CHF5074Joel Ross, Bruno P. Imbimbo, Mercedes Fernández et al.|Alzheimer s & Dementia|2013Cited by 3
P3‐411: Safety and pharmacokinetics of CHF5074, a novel gamma‐secretase modulator, after single oral administration to healthy humansBruno P. Imbimbo, Joel Ross, Donna Mackintosh et al.|Alzheimer s & Dementia|2010Cited by 1
P1‐269: A 12‐week, double‐blind, placebo‐controlled, dose‐range finding study of CHF5074 in patients with mild cognitive impairmentJoel Ross, Bruno P. Imbimbo, Daniela Casula et al.|Alzheimer s & Dementia|2012Cited by 0